Oncopeptides AB (LTS:0RN4) Total Assets : kr244.19 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Oncopeptides AB Total Assets?

Oncopeptides AB's Total Assets for the quarter that ended in Dec. 2024 was kr244.19 Mil.

During the past 12 months, Oncopeptides AB's average Total Assets Growth Rate was 1.10% per year. During the past 3 years, the average Total Assets Growth Rate was -4.40% per year. During the past 5 years, the average Total Assets Growth Rate was -5.20% per year. During the past 10 years, the average Total Assets Growth Rate was 41.80% per year.

During the past 11 years, Oncopeptides AB's highest 3-Year average Total Assets Growth Rate was 303.10%. The lowest was -15.60%. And the median was 34.15%.

Total Assets is connected with ROA %. Oncopeptides AB's annualized ROA % for the quarter that ended in Dec. 2024 was -118.46%. Total Assets is also linked to Revenue through Asset Turnover. Oncopeptides AB's Asset Turnover for the quarter that ended in Dec. 2024 was 0.04.

Oncopeptides AB Total Assets Historical Data

The historical data trend for Oncopeptides AB's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB Total Assets Chart

Oncopeptides AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Assets

Get a 7-Day Free Trial

946.76

439.38

385.32

238.38

244.19

Oncopeptides AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Assets	Get a 7-Day Free Trial															238.38	199.69	452.92	319.21	244.19

Oncopeptides AB Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Oncopeptides AB's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (A: Dec. 2024 )	+	Total Liabilities (A: Dec. 2024 )
	=	54.285	+	189.907
	=	244.19

Oncopeptides AB's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2024 )	+	Total Liabilities (Q: Dec. 2024 )
	=	54.285	+	189.907
	=	244.19

Oncopeptides AB (LTS:0RN4) Total Assets Explanation

Total Assets is connected with ROA %.

Oncopeptides AB's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %	=	Net Income (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	-333.704	/	( (319.209	+	244.192)	/ 2 )
	=	-333.704	/	281.7005
	=	-118.46 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Oncopeptides AB's Asset Turnover for the quarter that ended in Dec. 2024 is

	Asset Turnover
=	Revenue (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
=	9.914	/	( (319.209	+	244.192)	/ 2 )
=	9.914	/	281.7005
=	0.04

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Oncopeptides AB Total Assets Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncopeptides AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (LTS:0RN4) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

ONCO:Sweden OND:Germany

Address

Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53

Website

https://www.oncopeptides.com

Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.

Oncopeptides AB Headlines

No Headlines